Grifols offers 53% premium in $3.4 billion offer for Talecris
This article was originally published in Scrip
Executive Summary
Spain's Grifols has agreed to acquire Talecris Biotherapeutics in a cash and stock deal worth about $3.4 billion, which would create a close rival to second-placed CSL in the $12 billion global plasma derivatives market. Factoring in debt and cash, the deal values Talecris at about $4 billion.